{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:58:00Z","timestamp":1792112280534,"version":"4.4.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2011,9,23]],"date-time":"2011-09-23T00:00:00Z","timestamp":1316736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health","doi-asserted-by":"publisher","award":["K12 HD001262-12"],"award-info":[{"award-number":["K12 HD001262-12"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Human Development sponsored Women's Reproductive Health Research Career Development Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Imatinib mesylate is the first in a family of highly effective, minimally toxic, targeted agents used widely to treat Philadelphia-positive leukemias and selected other cancers, leading to a steady rise in the prevalence of patients using such therapy. Because failure of therapy would require conventional gonadotoxic chemotherapeutics, many female patients using imatinib may choose to preserve fertility. Herein, we provide evidence of a potential negative effect of imatinib on ovarian function by reporting the first case of a woman who showed a severely compromised ovarian response to gonadotropin stimulation while on imatinib, with a normal ovarian response after stopping this medication.<\/jats:p>","DOI":"10.1634\/theoncologist.2011-0137","type":"journal-article","created":{"date-parts":[[2011,9,24]],"date-time":"2011-09-24T05:28:35Z","timestamp":1316842115000},"page":"1422-1427","source":"Crossref","is-referenced-by-count":54,"title":["Will Imatinib Compromise Reproductive Capacity?"],"prefix":"10.1093","volume":"16","author":[{"given":"Alberuni M.","family":"Zamah","sequence":"first","affiliation":[{"name":"a UCSF Medical Center, Center for Reproductive Health, San Francisco, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mauro","sequence":"additional","affiliation":[{"name":"b OHSU Medical Center, Knight Cancer Institute, Portland, Oregon, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Druker","sequence":"additional","affiliation":[{"name":"b OHSU Medical Center, Knight Cancer Institute, Portland, Oregon, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kutluk","family":"Oktay","sequence":"additional","affiliation":[{"name":"c New York Medical College, Institute for Fertility Preservation, Valhalla, New York, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrill J.","family":"Egorin","sequence":"additional","affiliation":[{"name":"d University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelle I.","family":"Cedars","sequence":"additional","affiliation":[{"name":"a UCSF Medical Center, Center for Reproductive Health, San Francisco, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell P.","family":"Rosen","sequence":"additional","affiliation":[{"name":"a UCSF Medical Center, Center for Reproductive Health, San Francisco, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,9,23]]},"reference":[{"key":"2021122304021058300_B1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1570-0232(03)00206-X","article-title":"Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma","volume":"791","author":"Parise","year":"2003","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2021122304021058300_B2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7827-7-35","article-title":"The effect of follicular fluid hormones on oocyte recovery after ovarian stimulation: FSH level predicts oocyte recovery","volume":"7","author":"Rosen","year":"2009","journal-title":"Reprod Biol Endocrinol"},{"key":"2021122304021058300_B3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ydbio.2009.06.022","article-title":"Phosphorylation and consequent stimulation of the tyrosine kinase c-Abl by PKA in mouse spermatozoa; its implications during capacitation","volume":"333","author":"Baker","year":"2009","journal-title":"Dev Biol"},{"key":"2021122304021058300_B4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2605.2007.00755.x","article-title":"Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat","volume":"30","author":"Nurmio","year":"2007","journal-title":"Int J Androl"},{"key":"2021122304021058300_B5","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJM200411113512024","article-title":"Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome","volume":"351","author":"Seshadri","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122304021058300_B6","doi-asserted-by":"crossref","first-page":"1120.e15","DOI":"10.1016\/j.fertnstert.2010.08.060","article-title":"Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty","volume":"95","author":"Mariani","year":"2011","journal-title":"Fertil Steril"},{"key":"2021122304021058300_B7","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.6004\/jnccn.2009.0069","article-title":"Issues of imatinib and pregnancy outcome","volume":"7","author":"Apperley","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122304021058300_B8","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"key":"2021122304021058300_B9","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMc0707841","article-title":"Primary ovarian insufficiency associated with imatinib therapy","volume":"358","author":"Christopoulos","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122304021058300_B10","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1056\/NEJMc080707","article-title":"More on ovarian insufficiency with imatinib","volume":"358","author":"Malozowski","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122304021058300_B11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1210\/er.2005-0015","article-title":"The science behind 25 years of ovarian stimulation for in vitro fertilization","volume":"27","author":"Macklon","year":"2006","journal-title":"Endocr Rev"},{"key":"2021122304021058300_B12","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid leukemia treated with imatinib","volume":"24","author":"Ault","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122304021058300_B13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1530\/rep.1.00960","article-title":"Formation of ovarian follicular fluid may be due to the osmotic potential of large glycosaminoglycans and proteoglycans","volume":"132","author":"Clarke","year":"2006","journal-title":"Reproduction"},{"key":"2021122304021058300_B14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/edrv-17-2-121","article-title":"Regulation of ovarian follicular development in primates: Facts and hypotheses","volume":"17","author":"Gougeon","year":"1996","journal-title":"Endocr Rev"},{"key":"2021122304021058300_B15","first-page":"200","article-title":"Initial and cyclic recruitment of ovarian follicles","volume":"21","author":"McGee","year":"2000","journal-title":"Endocr Rev"},{"key":"2021122304021058300_B16","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122304021058300_B17","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122304021058300_B18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia","volume":"105","author":"Druker","year":"2000","journal-title":"J Clin Invest"},{"key":"2021122304021058300_B19","first-page":"3034","article-title":"Approval summary: Imatinib mesylate in the treatment of metastatic and\/or unresectable malignant gastrointestinal stromal tumors","volume":"8","author":"Dagher","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2021122304021058300_B20","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3816\/CBC.2008.n.062","article-title":"A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338","volume":"8","author":"Chew","year":"2008","journal-title":"Clin Breast Cancer"},{"key":"2021122304021058300_B21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/cncr.23605","article-title":"Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: A Hoosier Oncology Group trial","volume":"113","author":"Matei","year":"2008","journal-title":"Cancer"},{"key":"2021122304021058300_B22","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1158\/1078-0432.CCR-07-1269","article-title":"Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases","volume":"13","author":"Mathew","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122304021058300_B23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3816\/CBC.2009.n.040","article-title":"Phase II trial of docetaxel plus imatinib mesylate in the treatment of patients with metastatic breast cancer","volume":"9","author":"Yardley","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"2021122304021058300_B24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat Biotechnol"},{"key":"2021122304021058300_B25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2007.09.017","article-title":"Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors","volume":"108","author":"Chu","year":"2008","journal-title":"Gynecol Oncol"},{"key":"2021122304021058300_B26","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood-2003-09-3032","article-title":"Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a Children's Oncology Group phase 1 study","volume":"104","author":"Champagne","year":"2004","journal-title":"Blood"},{"key":"2021122304021058300_B27","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122304021058300_B28","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/nm.2033","article-title":"Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death","volume":"15","author":"Gonfloni","year":"2009","journal-title":"Nat Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-0137","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0137","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/10\/1422\/41856666\/oncolo_16_10_1422.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/10\/1422\/41856666\/oncolo_16_10_1422.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T09:25:49Z","timestamp":1640251549000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/16\/10\/1422\/6401810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,23]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2011,9,23]]},"published-print":{"date-parts":[[2011,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0137","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,10,1]]},"published":{"date-parts":[[2011,9,23]]}}}